Entrada Therapeutics (TRDA) Total Liabilities (2020 - 2026)

Entrada Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $64.7 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 6.58% year-over-year to $64.7 million in Q1 2026; TTM through Mar 2026 was $64.7 million, a 6.58% decrease from a year earlier, with the FY2025 full-year figure at $71.2 million, down 27.04% from the prior year.
• Total Liabilities eased to $64.7 million in Q1 2026 per TRDA's latest filing, from $71.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $287.1 million in Q2 2023 and bottomed at $39.3 million in Q1 2022.
• The 5-year median for Total Liabilities is $72.2 million (2025), against an average of $125.2 million.
• Across the five-year window, Total Liabilities surged 619.88% in 2023 and sank 71.34% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $39.5 million in 2022, then surged by 474.23% to $226.8 million in 2023, then sank by 56.95% to $97.6 million in 2024, then fell by 27.04% to $71.2 million in 2025, then decreased by 9.24% to $64.7 million in 2026.
• Per Business Quant, the three latest TRDA Total Liabilities figures stand at $64.7 million (Q1 2026), $71.2 million (Q4 2025), and $72.2 million (Q3 2025).